Premium
Off‐label use of biologicals in the management of inflammatory oral mucosal disease
Author(s) -
O’Neill Iain David
Publication year - 2008
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/j.1600-0714.2008.00693.x
Subject(s) - medicine , efalizumab , infliximab , etanercept , adalimumab , psoriasis , dermatology , stomatitis , cicatricial pemphigoid , mucosal melanoma , immunology , pemphigoid , rheumatoid arthritis , tumor necrosis factor alpha , melanoma , antibody , bullous pemphigoid , cancer research
The recent development of novel biologic immunomodulators effective in the treatment of immune‐mediated inflammatory conditions has led to their widespread use in rheumatology and dermatology. These include the tumour necrosis factor‐α antagonists, infliximab, etanercept and adalimumab and the T‐cell modulator modifiers efalizumab and alefacept. In dermatology, although these agents are licensed only for psoriasis, increasingly off‐label use has extended to a number of conditions in which oral mucosal disease is a significant component. These include Behçet’s disease, recurrent apthous stomatitis, benign mucous membrane pemphigoid and lichen planus. This article provides a review of the current literature on such off‐label use in oral mucosal disease.